ABBOTT LABORATORIES
ABTPharma & biotechabbott.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Nov 4, 2026
Next reportJanuary 20, 2027after close · forecast 1.655 $/share
Revenue
$13.01B
▲ +14.5% vs prior year YoY
Net income
$920.00M
▼ -44.0% vs prior year YoY
EPS
0.53$
▼ -43.6% vs prior year YoY
Net margin
7.1%
▼ -7.4 pp vs prior year YoY
Revenue▲ +14.5%
Margins (% of revenue)GrossOperatingNet
Net income▼ -44.0%
EPS▼ -43.6%
Financial statements
View 10-Q filed November 4, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $10.97B | $10.36B | $11.14B | $11.37B | $11.46B | $11.16B | $12.59B | $13.01B | ▲ +14.5% |
| Gross profit | $6.03B | $5.89B | $6.29B | $6.29B | $6.54B | $6.27B | $7.27B | $7.38B | ▲ +17.3% |
| Operating income | $1.91B | $1.69B | $2.05B | $2.06B | $2.25B | $1.34B | $1.69B | $1.36B | ▼ -34.0% |
| Net income | $9.23B | $1.32B | $1.78B | $1.64B | $1.78B | $1.08B | $928.00M | $920.00M | ▼ -44.0% |
| R&D | $749.00M | $716.00M | $725.00M | $766.00M | $735.00M | $767.00M | $892.00M | $920.00M | ▲ +20.1% |
| EPS (diluted) | — | 0.76 $ | 1.01 $ | 0.94 $ | — | 0.61 $ | 0.53 $ | 0.53 $ | ▼ -43.6% |
| Margins (% of revenue) | |||||||||
| Gross | 55.0 % | 56.9 % | 56.4 % | 55.4 % | 57.0 % | 56.2 % | 57.7 % | 56.8 % | ▲ +1.4 pt |
| Operating | 17.4 % | 16.3 % | 18.4 % | 18.1 % | 19.6 % | 12.0 % | 13.4 % | 10.4 % | ▼ -7.7 pt |
| Net | 84.1 % | 12.8 % | 16.0 % | 14.5 % | 15.5 % | 9.6 % | 7.4 % | 7.1 % | ▼ -7.4 pt |
| Balance sheet | |||||||||
| Assets | $81.41B | $81.45B | $84.00B | $84.18B | $86.71B | $110.43B | $109.22B | $108.25B | ▲ +28.6% |
| Liabilities | $33.51B | $32.38B | $33.17B | $32.92B | $33.94B | $57.73B | $57.45B | $56.62B | ▲ +72.0% |
| Equity | $47.90B | $49.06B | $50.83B | $51.26B | $52.77B | $52.70B | $51.76B | $51.62B | ▲ +0.7% |
| Cash | $7.62B | $6.53B | $6.95B | $7.51B | $8.52B | $6.80B | $5.10B | $4.05B | ▼ -46.1% |
| Capital | |||||||||
| Shares outstanding | 1.73B | 1.74B | 1.74B | 1.74B | 1.74B | 1.74B | 1.73B | 1.73B | ▼ -0.4% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.